HBOT for TBI & Concussion: 2026 Military Data & Clinical Outcomes

The TBI Burden

In the largest double-blind TBI trial to date, HBOT patients improved their neurobehavioral symptom scores nearly three times more than the control group. An estimated 2.8 million Americans sustain a traumatic brain injury each year, and 5.3 million live with TBI-related disability. Among military veterans, blast-induced mild TBI affects 400,000+ service members. The clinical data is now substantial enough to assess what HBOT actually delivers.

HBOT has emerged as one of the most actively studied interventions for TBI, with particular momentum in both the military medicine community and civilian research settings. A 2026 comprehensive review synthesized 74 studies, finding “mixed but promising” evidence and calling for protocol standardization.¹²

What Does the Research Say?

Key Studies and Their Data

Weaver et al., 2025 – The Latest Double-Blind RCT

The most methodologically rigorous trial in this field to date enrolled 47 participants with persistent symptoms after brain injury, randomized to 40 HBOT sessions (1.5 ATA, 60 min, 100% O2) or sham over 12 weeks.¹

“In the largest double-blind trial to date, HBOT patients improved their neurobehavioral symptom scores nearly three times more than those receiving sham treatment (10.6 vs 3.6 points, p=0.01), with additional improvements in olfaction, anxiety, sleep, and vestibular complaints.”
Weaver et al., 2025, Scientific Reports

• Primary outcome: NSI change at 13 weeks – HBOT 10.6 ± 10.6 vs sham 3.6 ± 5.9 (mean difference 7.0, 95% CI 1.7-12.3, p=0.01)
• Secondary improvements: olfaction, anxiety, sleep difficulties, vestibular complaints
• Both groups improved: depression, headaches, PTSD symptoms, physical quality of life
• Notable: the authors suggest 80 sessions may be superior to 40 for long-term outcomes

Cochrane Review – Bennett et al., 2012

The most comprehensive systematic review pooled 7 randomized trials with 571 patients.³ Key findings:

• Mortality: RR 0.69 (95% CI 0.54-0.88, p=0.003) – 31% mortality risk reduction
• Number needed to treat: 7 (to prevent one additional death)
• Unfavourable outcome at 1 month: RR 0.74 (95% CI 0.61-0.88, p=0.001)
• GCS improvement: MD 2.68 points (95% CI 1.84-3.52, p<0.0001)
• Pulmonary impairment: 13% HBOT vs 0% control (p=0.007) – the primary safety signal

Chaturvedi et al., 2024 – Acute Moderate TBI RCT

This RCT enrolled adults with moderate TBI and added 10 consecutive daily HBOT sessions (1.4 ATA, 60 min) to standard care.² Results:

• GCS at discharge: 14.37 ± 0.51 (HBOT) vs 13.40 ± 0.84 (control), p<0.001
• GOS-E at 3 months: 7.62 ± 0.51 (HBOT) vs 6.40 ± 1.50 (control), p<0.001

“Patients receiving early HBOT after moderate TBI scored a full point higher on the Glasgow Coma Scale at discharge and maintained significantly better functional outcomes at 3 months.”
Chaturvedi et al., 2024, Asian Journal of Neurosurgery

Shahid et al., 2025 – Cognitive Outcomes Meta-Analysis

This meta-analysis specifically targeted neurocognitive outcomes across 4 studies and 250 TBI patients.⁵ Results were significant across all domains tested:

Brain Imaging Evidence

One of the strongest arguments for HBOT in TBI comes from objective brain imaging. SPECT (single photon emission computed tomography) scans consistently show:

• Pre-sessions: Areas of decreased perfusion (blood flow) corresponding to injury sites
• Post-sessions: Increased perfusion in previously hypoperfused regions
• Correlation: Areas of improved perfusion correspond to cognitive domains showing improvement on neuropsychological testing

This objective imaging data is particularly important for TBI because it provides biological evidence of treatment effect independent of patient self-report. Before and after imaging results show visible changes correlating with clinical improvement.

The “Sham” Controversy

A critical issue in HBOT-TBI research: the standard “sham” condition (1.2 ATA, room air) may itself be therapeutic. This has important implications for interpreting trial results:

• Both groups improve: In almost every TBI trial, sham groups show significant within-group improvement alongside HBOT groups
• Biggs 2021 analysis: Placebo effects account for approximately one-third of observed benefits, but a genuine therapeutic benefit remains⁸
• Harch 2022 dose analysis: Even 1.2-1.3 ATA pressurized air produced some positive results in one study⁹
• Key implication: “No difference from sham” may not mean “no effect” – it may mean pressurized air also works. This particularly affects interpretation of the Cifu 2014 military trials at 2.0 ATA

Protocol Comparison

Post-Concussion Syndrome: What the Numbers Say

For athletes dealing with concussion recovery, HBOT is increasingly part of return-to-play protocols. The Harch 2020 crossover RCT of 63 patients documented significant improvement across all seven outcome measures tracked: Neurobehavioral Symptom Inventory, Memory Index, Hamilton Depression Scale, Hamilton Anxiety Scale, PTSD Checklist, Pittsburgh Sleep Quality Index, and Quality of Life after Brain Injury, with improvements persisting at least 2 months post-sessions.⁶

The 2022 pediatric trial enrolled 25 children aged 8-15 with PPCS from mild-moderate TBI (6 months to 10 years prior) and randomized them to 60 sessions HBOT vs sham in a double-blind design.⁷ Results: general cognitive score (d=0.598, p=0.01), executive function (d=0.739, p=0.003), planning/organizing (d=1.09, p=0.007), and emotional regulation (d=-0.676, p=0.04). MRI confirmed microstructural brain changes in key regions.

Current Access and Limitations

TBI remains an off-label indication for HBOT. This means:

• Insurance does not cover HBOT for TBI (with rare exceptions through VA pilot programs)
• Cost: A 40-60 session course costs $8,000-$24,000 out of pocket
• Access: Effective sessions require a hard chamber at 1.5-2.0 ATA. Home soft chambers at 1.3 ATA have not been validated for TBI in published research

Congressional efforts to fund VA HBOT programs for TBI have gained bipartisan support, and several VA medical centers now offer HBOT for TBI through research protocols. The HOBIT adaptive Phase II trial (NCT02407028) is ongoing to determine optimal protocols for severe TBI, potentially paving the way for a definitive Phase III trial.

Sources

1. Weaver LK, Ziemnik R, Deru K, Russo AA. “A double-blind randomized trial of hyperbaric oxygen for persistent symptoms after brain injury.” Scientific Reports. 2025;15. DOI: 10.1038/s41598-025-86631-6
2. Chaturvedi J, Mago V, Gupta M, et al. “Hyperbaric Oxygen Therapy in Moderate Traumatic Brain Injury: A Randomized Controlled Trial.” Asian Journal of Neurosurgery. 2024. DOI: 10.1055/s-0044-1791997
3. Bennett MH, Trytko BE, Jonker B. “Hyperbaric oxygen therapy for the adjunctive treatment of traumatic brain injury.” Cochrane Database of Systematic Reviews. 2012;12:CD004609. DOI: 10.1002/14651858.CD004609.pub3
4. Wang F, Wang Y, Sun T, Yu HL. “Hyperbaric oxygen therapy for the treatment of traumatic brain injury: a meta-analysis.” Neurological Sciences. 2016;37:693-701. DOI: 10.1007/s10072-015-2460-2
5. Shahid S, et al. “HBOT for neurocognitive deficits following TBI: a systematic review and meta-analysis.” Annals of Medicine and Surgery. 2025. DOI: 10.1097/MS9.0000000000003902
6. Harch PG, Andrews SR, Rowe CJ, et al. “Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion syndrome: a randomized controlled trial.” Medical Gas Research. 2020;10(1):8-20. DOI: 10.4103/2045-9912.279978
7. Hadanny A, Catalogna M, Yaniv S, et al. “Hyperbaric oxygen therapy in children with post-concussion syndrome improves cognitive and behavioral function.” Scientific Reports. 2022;12:15233. DOI: 10.1038/s41598-022-19395-y
8. Biggs AT, Dainer H, Littlejohn LF. “Effect Sizes for Symptomatic and Cognitive Improvements in TBI Following HBOT.” Journal of Applied Physiology. 2021. DOI: 10.1152/japplphysiol.01084.2020
9. Harch PG. “Systematic Review and Dosage Analysis: HBOT Efficacy in Mild TBI Persistent Postconcussion Syndrome.” Frontiers in Neurology. 2022;13:815056. DOI: 10.3389/fneur.2022.815056
10. Cifu DX, et al. “The Effect of Hyperbaric Oxygen on Persistent Postconcussion Symptoms.” Journal of Head Trauma Rehabilitation. 2014. DOI: 10.1097/HTR.0b013e3182a6aaf0
11. Defense and Veterans Brain Injury Center (DVBIC). “DoD TBI Worldwide Numbers.”
12. Jusoh AF, et al. “HBOT in TBI: A Comprehensive Structure Review.” Undersea and Hyperbaric Medicine. 2026;53(1):65-82. DOI: 10.22462/799

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website